High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients

Antimicrob Agents Chemother. 2002 Dec;46(12):4009-12. doi: 10.1128/AAC.46.12.4009-4012.2002.

Abstract

To assess the relationship between antiretroviral drug exposure and lipodystrophy, 69 human immunodeficiency virus type 1-infected patients receiving nelfinavir were investigated cross-sectionally. Lipodystrophy was defined by patients' self-report. Nelfinavir trough concentrations in plasma were significantly related to overall lipodystrophy and peripheral fat wasting scores and appeared to be an independent risk factor for lipodystrophy

Publication types

  • Clinical Trial

MeSH terms

  • Body Composition
  • Female
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / adverse effects*
  • HIV-1*
  • Humans
  • Lipodystrophy / chemically induced*
  • Male
  • Middle Aged
  • Nelfinavir / adverse effects*
  • Risk Factors

Substances

  • HIV Protease Inhibitors
  • Nelfinavir